141 related articles for article (PubMed ID: 29567879)
1. Role of calcium-sensing receptor, Galectin-3, Cyclin D1, and Ki-67 immunohistochemistry to favor in the diagnosis of parathyroid carcinoma.
Sungu N; Dogan HT; Kiliçarslan A; Kiliç M; Polat S; Tokaç M; Akbaba S; Parlak Ö; Balci S; Ögüt B; Çakir B
Indian J Pathol Microbiol; 2018; 61(1):22-26. PubMed ID: 29567879
[TBL] [Abstract][Full Text] [Related]
2. Parafibromin, galectin-3, PGP9.5, Ki67, and cyclin D1: using an immunohistochemical panel to aid in the diagnosis of parathyroid cancer.
Truran PP; Johnson SJ; Bliss RD; Lennard TW; Aspinall SR
World J Surg; 2014 Nov; 38(11):2845-54. PubMed ID: 25002250
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous expression analysis of vitamin D receptor, calcium-sensing receptor, cyclin D1, and PTH in symptomatic primary hyperparathyroidism in Asian Indians.
Varshney S; Bhadada SK; Saikia UN; Sachdeva N; Behera A; Arya AK; Sharma S; Bhansali A; Mithal A; Rao SD
Eur J Endocrinol; 2013 Jul; 169(1):109-16. PubMed ID: 23660642
[TBL] [Abstract][Full Text] [Related]
4. Filamin A and parafibromin expression in parathyroid carcinoma.
Storvall S; Leijon H; Ryhänen EM; Vesterinen T; Heiskanen I; Schalin-Jäntti C; Arola J
Eur J Endocrinol; 2021 Oct; 185(6):803-812. PubMed ID: 34606470
[TBL] [Abstract][Full Text] [Related]
5. Parafibromin, APC, and MIB-1 Are Useful Markers for Distinguishing Parathyroid Carcinomas From Adenomas.
Hosny Mohammed K; Siddiqui MT; Willis BC; Zaharieva Tsvetkova D; Mohamed A; Patel S; Sharma J; Weber C; Cohen C
Appl Immunohistochem Mol Morphol; 2017; 25(10):731-735. PubMed ID: 27490759
[TBL] [Abstract][Full Text] [Related]
6. Differential expression of the calcium sensing receptor and combined loss of chromosomes 1q and 11q in parathyroid carcinoma.
Haven CJ; van Puijenbroek M; Karperien M; Fleuren GJ; Morreau H
J Pathol; 2004 Jan; 202(1):86-94. PubMed ID: 14694525
[TBL] [Abstract][Full Text] [Related]
7. Decrease in vitamin D receptor and calcium-sensing receptor in highly proliferative parathyroid adenomas.
Yano S; Sugimoto T; Tsukamoto T; Chihara K; Kobayashi A; Kitazawa S; Maeda S; Kitazawa R
Eur J Endocrinol; 2003 Apr; 148(4):403-11. PubMed ID: 12656660
[TBL] [Abstract][Full Text] [Related]
8. Defining a molecular phenotype for benign and malignant parathyroid tumors.
Fernandez-Ranvier GG; Khanafshar E; Tacha D; Wong M; Kebebew E; Duh QY; Clark OH
Cancer; 2009 Jan; 115(2):334-44. PubMed ID: 19107770
[TBL] [Abstract][Full Text] [Related]
9. Expression of Ki-67, galectin-3, fragile histidine triad, and parafibromin in malignant and benign parathyroid tumors.
Wang O; Wang CY; Shi J; Nie M; Xia WB; Li M; Jiang Y; Guan H; Meng XW; Xing XP
Chin Med J (Engl); 2012 Aug; 125(16):2895-901. PubMed ID: 22932087
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemistry in Diagnostic Parathyroid Pathology.
Erickson LA; Mete O
Endocr Pathol; 2018 Jun; 29(2):113-129. PubMed ID: 29626276
[TBL] [Abstract][Full Text] [Related]
11. Cyclin D1 in well differentiated thyroid tumour of uncertain malignant potential.
Lamba Saini M; Weynand B; Rahier J; Mourad M; Hamoir M; Marbaix E
Diagn Pathol; 2015 Apr; 10():32. PubMed ID: 25907675
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of CASR expression and global loss of parafibromin staining are strong negative determinants of prognosis in parathyroid carcinoma.
Witteveen JE; Hamdy NA; Dekkers OM; Kievit J; van Wezel T; Teh BT; Romijn JA; Morreau H
Mod Pathol; 2011 May; 24(5):688-97. PubMed ID: 21240254
[TBL] [Abstract][Full Text] [Related]
13. Expression of PRAD1/cyclin D1, retinoblastoma gene products, and Ki67 in parathyroid hyperplasia caused by chronic renal failure versus primary adenoma.
Tominaga Y; Tsuzuki T; Uchida K; Haba T; Otsuka S; Ichimori T; Yamada K; Numano M; Tanaka Y; Takagi H
Kidney Int; 1999 Apr; 55(4):1375-83. PubMed ID: 10201002
[TBL] [Abstract][Full Text] [Related]
14. Should parafibromin staining replace HRTP2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma?
Cetani F; Ambrogini E; Viacava P; Pardi E; Fanelli G; Naccarato AG; Borsari S; Lemmi M; Berti P; Miccoli P; Pinchera A; Marcocci C
Eur J Endocrinol; 2007 May; 156(5):547-54. PubMed ID: 17468190
[TBL] [Abstract][Full Text] [Related]
15. Modulation of cyclin D1 expression in human tumoral parathyroid cells: effects of growth factors and calcium sensing receptor activation.
Corbetta S; Eller-Vainicher C; Vicentini L; Lania A; Mantovani G; Beck-Peccoz P; Spada A
Cancer Lett; 2007 Sep; 255(1):34-41. PubMed ID: 17482347
[TBL] [Abstract][Full Text] [Related]
16. Reduced Calcium Sensing Receptor (CaSR) Expression Is Epigenetically Deregulated in Parathyroid Adenomas.
Singh P; Bhadada SK; Dahiya D; Arya AK; Saikia UN; Sachdeva N; Kaur J; Brandi ML; Rao SD
J Clin Endocrinol Metab; 2020 Sep; 105(9):3015-24. PubMed ID: 32609827
[TBL] [Abstract][Full Text] [Related]
17. Clinical Impact of p27
Sengul Aycicek G; Aydogan BI; Sahin M; Cansız Ersoz C; Sak SD; Baskal N
Endocr Pathol; 2018 Sep; 29(3):250-258. PubMed ID: 29589297
[TBL] [Abstract][Full Text] [Related]
18. Galectin-3 and Ki-67 expression in multiglandular parathyroid lesions.
Saggiorato E; Bergero N; Volante M; Bacillo E; Rosas R; Gasparri G; Orlandi F; Papotti M
Am J Clin Pathol; 2006 Jul; 126(1):59-66. PubMed ID: 16753595
[TBL] [Abstract][Full Text] [Related]
19. Parafibromin immunostainings of parathyroid tumors in clinical routine: a near-decade experience from a tertiary center.
Juhlin CC; Nilsson IL; Lagerstedt-Robinson K; Stenman A; Bränström R; Tham E; Höög A
Mod Pathol; 2019 Jul; 32(8):1082-1094. PubMed ID: 30923346
[TBL] [Abstract][Full Text] [Related]
20. Molecular Characteristics of Large Parathyroid Adenomas.
Agarwal A; Pradhan R; Kumari N; Krishnani N; Shukla P; Gupta SK; Chand G; Mishra A; Agarwal G; Verma AK; Mishra SK
World J Surg; 2016 Mar; 40(3):607-14. PubMed ID: 26669787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
